BioMarin Pharmaceutical Inc. — Third Quarter 2026 Earnings Summary

BioMarin Pharmaceutical Inc. reported third-quarter 2026 total revenues of $1.025 billion, representing a 32% year-over-year increase driven by the acquisition of Amicus Therapeutics and strong demand for its metabolic and skeletal condition therapies. The company announced a PDUFA action date of May 30, 2027, for the expansion of VOXZOGO to treat hypochondroplasia and updated its full-year 2026 guidance to reflect order timing uncertainties and significant in-process research and development charges. Despite a GAAP net loss of $123 million due to acquisition-related costs and amortization, the company achieved Non-GAAP income of $45 million and highlighted the addition of four new investigational assets to its pipeline.